All Outputs (3)

Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study (2024)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Nguyen Van-Tam, J. S., Abhishek, A., & . (2024). Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study. Rheumatology, Article keae160. https://doi.org/10.1093/rheumatology/keae160

Objective The uptake and safety of pneumococcal vaccination in people with immune mediated inflammatory diseases (IMIDs) is poorly understood. We investigated the UK wide pneumococcal vaccine uptake in adults with IMIDs and explored the association b... Read More about Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study.

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients (2024)
Journal Article
Standing, J. F., Buggiotti, L., Guerra-Assunção, J. A., Woodall, M., Ellis, S., Agyeman, A. A., …Breuer, J. (2024). Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients. Nature Communications, 15, Article 1652. https://doi.org/10.1038/s41467-024-45641-0

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n=253) or Usual Care (n... Read More about Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial (2024)
Journal Article
Png, M. E., Harris, V., Grabey, J., Hart, N. D., Jani, B. D., Butler, D., …Petrou, S. (in press). Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial. British Journal of General Practice, Article 0444. https://doi.org/10.3399/bjgp.2023.0444

The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of SARS-CoV-2, has not been established in vaccinated populations. To evaluate the cost-effectiveness of molnupiravir relative to usual care alone among mainly vaccinated c... Read More about Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial.